Search Results 71-80 of 17316 for egfr

1. Radiogenomics: Exploring MRI's potential for predicting heterogeneous tumor biology - Mayo Clinic

   ... (EGFR) amplification at the voxel level throughout different regions of individuals' tumors. EGFR is a key genetic driver of GBM . Unlike similar models ...

2. A Study Using Avelumab In Non-Small Cell Lung Cancer That Has Progressed - Mayo Clinic

   ... EGFR-targeting tyrosine kinase inhibitor (TKI) given before or after ... Subjects whose disease harbors an activating EGFR mutation who received an EGFR ...

3. Pemetrexed (intravenous route) - Side effects & uses - Mayo Clinic

   ... EGFR or ALK gene. This medicine is also used in combination with cisplatin as first treatment for non-squamous NSCLC that has spread (locally advanced or ...

4. A Study To Explore The Renal Safety Of Visipaque Injection 320 MgI/mL In Patients With Chronic Kidney Disease - Mayo Clinic

   Has a documented diagnosis of stage III or IV (defined as 30≤ estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m² and 15 ≤eGFR <30 mL/min/1.73 ...

5. CARDIOLOGY DIAGNOSTIC REFERRAL FORM 1

   The patient is able to brisk walk on an inclined treadmill? Reviewed Relative and Absolute Contraindications? Diabetes. Creatinine level eGfr and date: ...

6. Publications - Xia Zhou, M.B., Ph.D. - Mayo Clinic

   HDAC6 regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation in renal epithelial cells. PLoS One. 2012; 7 (11):e49418 Epub ...

7. A Study To Evaluate Bardoxolone Methyl In Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) - Mayo Clinic

   ... eGFR decline of ≥ 2.0 mL/min/1.73 m^2 per year, based on historical eGFR data and medical monitor discretion);; The two eGFR values collected at Screen A ...

8. Analysis of Biomarkers in Type 1 Diabetes Mellitus - Mayo Clinic

   eGFR ≥ 60 ml/mt; Capable of providing informed consent. Exclusion Criteria: eGFR ≤ 60 ml/mt; Pregnancy. Participating Mayo Clinic locations. Study statuses ...

9. Visionary Study: Phase 3 Trial Of Sibeprenlimab In Immunoglobulin A Nephropathy (IgAN) - Mayo Clinic

   g/day. - eGFR ≥ 30 mL/min/1.73 m2, (for the exploratory cohort only: eGFR 20- <30 mL/min/1.73 m2), calculated using the CKD-EPI equation). Exclusion ...

10. A Study of Erlotinib as a Prevention in Trisomy 7 Positive Primary Sclerosing Cholangitis - Mayo Clinic

    Erlotinib (Tarceva) is a human EGFR type 1 tyrosine kinase inhibitor and offers greater survival benefit to EGFR positive patients. This study will assist ...